Aclaris Therapeutics

Aclaris Therapeutics — Products A–Z

• E — Eskata® (A-101 40%)
  • Generic: Hydrogen peroxide 40% topical solution
  • Indication: Raised seborrheic keratoses in adults (in-office use) — U.S. commercialization discontinued
  • Dose: In a single visit, apply to each lesion 4 times ~1 minute apart; if not cleared, may repeat ~3 weeks later.

• R — RHOFADE®
  • Generic: Oxymetazoline HCl 1% cream (topical alpha-1A agonist)
  • Indication: Persistent facial erythema of rosacea in adults (Aclaris acquired in 2018; divested in 2019)
  • Dose: Pea-sized amount once daily in a thin layer to cover the entire face, avoiding eyes and lips.

Investigational pipeline (not approved; dosing regimens are study-specific)

• A — A-101 45% Topical Solution
  • Generic: Hydrogen peroxide 45%
  • Indication (under study): Common warts (verruca vulgaris)
  • Dose: Investigational (office-applied regimen evaluated in Phase 3).

• A — ATI-052
  • Generic/Type: Bispecific antibody targeting TSLP and IL-4R
  • Indication (under study): Atopic / immunologic / respiratory diseases
  • Dose: Investigational (Phase 1 program).

• A — ATI-2138
  • Generic/Type: Oral ITK/JAK3 inhibitor
  • Indication (under study): Atopic dermatitis; company planning further development in alopecia areata and vitiligo
  • Dose: Investigational (Phase 2a data reported).

• B — Bosakitug (ATI-045)
  • Generic/Type: Anti-TSLP monoclonal antibody
  • Indication (under study): Atopic dermatitis (Phase 2 underway)
  • Dose: Investigational.

• L — Lepzacitinib (ATI-1777)
  • Generic/Type: Topical “soft” JAK1/JAK3 inhibitor (spray formulation)
  • Indication (under study): Atopic dermatitis (multiple Phase 2 studies)
  • Dose: Investigational.

• Z — Zunsemetinib (ATI-450)
  • Generic/Type: Oral MK2 pathway inhibitor
  • Indication: Immuno-inflammatory diseases program discontinued in 2023 (investigator-initiated oncology work noted separately)
  • Dose: Not marketed.

•